Tibotec

From Wikipedia, the free encyclopedia

Tibotec is a pharmaceutical company with a focus on research and development for the treatment of infectious diseases such as HIV (AIDS), and Hepatitis C. The company develops antiretroviral drugs for the treatment of AIDS.

History

In 1994, Rudi Pauwels (Rega Institute for Medical Research) founded Tibotec, together with his wife Carine Claeys, and their first co-workers Marie-Pierre de Béthune, Kurt Hertogs, and Hilde Azijn. In 1995 Paul Stoffels (Janssen Pharmaceutica) joined Tibotec. The company was acquired by Johnson & Johnson in April 2002. The name of the company is derived from the tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and -thione (TIBO) compounds discovered at the Rega Institute for Medical Research (Belgium).[1]

Drugs

  • TMC114 (darunavir, tradename Prezista), a protease inhibitor (PI), (recently approved by the FDA)
  • TMC125, (etravirine, tradename Intelence) a non-nucleoside reverse transcriptase inhibitor (NNRTI), (recently approved by the FDA)
  • TMC207, an experimental diarylquinoline anti-tuberculosis drug[2]
  • TMC278, (rilpivirine, tradename Edurant) an NNRTI, (approved by the FDA in May 2011)
  • TMC435 (simeprevir), an experimental HCV NS3/4A protease inhibitor being studied as a treatment for chronic hepatitis C in combination with pegylated interferon/ribavirin or with other direct-acting anti-HCV agents.[3]

Tibotec licensed TMC120 (dapivirine), an NNRTI, to the International Partnership for Microbicides for its development as a vaginal microbicide in March 2004.

See also

References

  1. ↑ Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, et al., Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives, Nature, 1990, 343, 470-474. doi:10.1038/343470a0
  2. ↑ Andries K, Verhasselt P, Guillemont J, et al. (2005), A diarylquinoline drug active on the ATP-synthase of Mycobacterium tuberculosis, Science 307 (5707): 223–27
  3. ↑ Zeuzem S, Berg T, Gane E, et al. (2012). TMC435 in HCV Genotype 1 Patients Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Final SVR24 Results of the ASPIRE Trial. 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, April 18–22, 2012. Abstract 2.

External links

CEOs and presidents
Selected subsidiaries
Major brands
  • Annual revenue: US$63.75 billion Increase 4.3% (FY 2008)
  • Annual net income: US$12.95 billion Increase 22.4% (FY 2008)
  • Employees: 118,700
  • Stock symbol: NYSE: JNJ
  • Website: www.jnj.com


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.